Back to Search
Dossier
SIRNA THERAPY FOR TRANSTHYRETIN (TTR) RELATED OCULAR AMYLOIDOSIS
InventionPending
2views
20Claims · 2 independent
§ Ⅰ
Dossier Overview
Applicant
Alnylam Pharmaceuticals, Inc.; KUMAMOTO UNIVERSITY
Inventor
Yukio Ando; Hirofumi Jono; Rene Alvarez; Dinah Wen-yee Sah
IPC Classification
C12N 15/113A61K 9/A61K 9/6A61K 9/10A61K 9/1271A61K 9/1272A61K 31/7088A61K 31/713A61K 47/54C7H 21/2C7J 43/C12N 5/79C12Q 1/6883
CPC Classification
C12N15/113A61K9/19A61K9/48A61K9/51A61K9/6A61K9/10A61K9/1271A61K9/1272A61K31/7088A61K31/713A61K47/554C7H21/2C7J43/C12N5/621C12Q1/6883C12N2310/14C12N2310/17C12N2310/314C12N2310/321C12N2310/346C12N2310/3515C12N2320/30C12N2503/2C12Q2600/158C12Q2600/178
The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.
Original (Chinese)
The invention relates to a method of treating ocular amyloidosis by reducing TTR expression in a subject by administering a double-stranded ribonucleic acid (dsRNA) that targets a TTR gene to the retinal pigment epithelium of the subject.
External Resources